Acute myocardial infarction (AMI) is complicated by cardiogenic shock (CS) in 7-10% of cases and the mortality rate is about 60-70% [13, 16] . Early revascula rization by percutaneous coronary inter vention (PCI) and intensive care includ ing positive inotropic agents, vasopres sors, and circulatory assist devices are routinely used to improve cardiac output and to prevent multiorgan failure [1, 5, 16] . Intraaortic balloon pump (IABP) is a commonly used mechanical support sys tem for patients with CS [25, 33] . Despite intensive therapy, these patients often de velop a systemic inflammatory response syndrome (SIRS) progressing to multiple organ dysfunction syndrome (MODS) and subsequent death due to multiple or gan failure [6, 39] . Identification of these patients in the ICU is clinically important [34] . Previous studies of patients with MODS or sepsis have shown the rele vance of several scoring systems such as the APACHE II [22, 42, 43] Originalien culation is more complex and laborious. However, a scoring system is only valid for a special group of patients when it has been validated on this group. The objec tive of the present study was to evaluate the predictive value of the APACHE II, APACHE III, Elebute-Stoner, SOFA, and SAPS II scores on mortality, determined on the day of diagnosis/admission of infarctionrelated CS patients and at the point of maximum value.
routinely used to improve cardiac output and to prevent multiorgan failure [1, 5, 16] . Intraaortic balloon pump (IABP) is a commonly used mechanical support sys tem for patients with CS [25, 33] . Despite intensive therapy, these patients often de velop a systemic inflammatory response syndrome (SIRS) progressing to multiple organ dysfunction syndrome (MODS) and subsequent death due to multiple or gan failure [6, 39] . Identification of these patients in the ICU is clinically important [34] . Previous studies of patients with MODS or sepsis have shown the rele vance of several scoring systems such as the APACHE II [22, 42, 43] , APACHE III [23] , Elebute-Stoner [9] , SOFA [40] , and SAPS II [24] as predictors of prognosis [41] . The APACHE II score was primar ily designed to predict the mortality of patients in ICUs, but attempts have been made to apply this score to patients with severe trauma [37] , abdominal complica tions [4] , chronic obstructive pulmonary disease [12] , acute pancreatitis [10] , sepsis [42] , and escalating SIRS after cardiac sur gery [43] . The APACHE III score can de scribe severity in more detail, but its cal culation is more complex and laborious. However, a scoring system is only valid for a special group of patients when it has been validated on this group. The objec tive of the present study was to evaluate the predictive value of the APACHE II, APACHE III, Elebute-Stoner, SOFA, and SAPS II scores on mortality, determined on the day of diagnosis/admission of infarctionrelated CS patients and at the point of maximum value.
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Methods
Inclusion and exclusion criteria
Patients treated with primary PCI for CS secondary to AMI, who required inotro pic and/or vasopressor support despite appropriate volume filling, were includ ed in the study. For the diagnosis of CS, the definitions of Hochman et al. [16] and Reynolds et al. [36] were used. The inclu sion and exclusion criteria are shown in . Tab. 1.
Study design
In this prospective observational study, carried out in a medical intensive care unit of a university hospital from 2004 to 2005, we consecutively enrolled 45 pa tients in CS. Patients underwent regu lar clinical assessment, complete inva sive monitoring, and frequent blood sam pling for laboratory markers. Datasets for the APACHE II, APACHE III, ElebuteStoner, SOFA, and SAPS II scores and for the patient parameters were calcu lated. Written informed consent was ob tained from all patients or their relatives. The trial was approved by the local eth ics committee.
Primary endpoints
The primary endpoint was the value of the initial and the maximum value of the APACHE II, APACHE III, ElebuteStoner, SOFA, and SAPS II scores in pre dicting mortality. Scores were collected at enrollment and then daily for 4 days. Demographic data, admission diagnosis, mechanical ventilation, IABP use, hemo dynamic parameters, survivors, and non survivors were recorded. The APACHE II, APACHE III, Elebute-Stoner, SOFA, and SAPS II scores were determined by the worst value found during the initial 24 h after ICU admission and also by the max imum value during the following 96 h.
A flowchart of the study is shown in . Fig. 1 .
Coronary angiography and PCI
Coronary angiography and PCI were per formed using standard techniques imme diately after admission. At the commence ment of PCI, all patients were given ace tylsalicylic acid (250 mg i.v.), glycopro teinIIb/IIIareceptor blocker (weight adjusted, i.v. abciximab or tirofiban) for 12-24 h, and heparin, 5,000-10,000 U i.v. bolus, followed by continuous infusion to maintain an activated partial thrombo plastin time of two to three times the nor mal value.
Intra-aortic balloon pump
A 40cc balloon IABP (IABP System 97, Datacope; Fairfield, NJ, USA,) was inserted when necessary (cardiologist's discretion) via the femoral artery using an 8French sheath immediately after PCI. Aortic counterpulsation was conti nued for a minimum of 48 h.
Statistical analysis
Quantitative values such as age or body mass index (BMI) and the different scor ing systems were tested on normal distri bution with the Kolomogrov-Smirnov test and the Shapiro-Wilk test. Differences in parametric values were tested with Stu dent's t test. Categorical variables were compared by the chisquared test. Some continuous variables (APACHE II, SOFA) were categorized into classes by selecting the best cutoffs (receiver operating char acteristic analysis, ROC). Discrimination was tested using the ROC curves and by evaluating areas under the curve (AUC) [14] . According to Hosmer and Leme show, AUCs between 0.7 and 0.8 were classified as"acceptable" and between 0.8 and 0.9 as"excellent" [18] .
For the different scoring systems and timepoints tested, the sensitivity and specificity values were calculated and cut off points giving the best sensitivity and specificity for mortality were determined. Each variable that was found to be sig nificant at p<0.05 by univariate analy ses was entered into a backward stepwise logistic regression model. Logistic regres sion analysis was performed to estimate the predictive ability of the APACHE II, 
Results
Baseline characteristics
Of the 45 patients in the study, 4 were excluded, because of acute heart failure due to other reasons. The overall morta lity rate was 44% in this study population. Percutaneous coronary intervention (i.e., PCI, PTCA, or stents) or IABP was per formed on most patients (about 70-75%), but did not differ between treatment groups. The sole significant difference between survivors and nonsurvivors was CPR, which was most often performed before PCI was carried out. The baseline characteristics and inflammatory param eters on admission are given in . Tab. 2.
Scores and survival
APACHE II score
Mean APACHE II scores on admis sion were 33.3±8.4 for nonsurvivors and 27.1±9.1 for survivors, determined at the time of CS diagnosis, and were signifi Abstract Background. Scoring systems in critical care patients are essential for prediction of outcome and for evaluation of therapy. In this study we determined the value of the APACHE II, APACHE III, Elebute-Stoner, SOFA, and SAPS II scoring systems in the prediction of mortality in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Material and methods. In this prospective, observational study, patients who were admitted to the ICU with CS complicating AMI were consecutively included. Data for the APACHE II, APACHE III, Elebute-Stoner, SOFA, and SAPS II scores were recorded on admission and during the following 96 h. Receiver operating characteristic curve analyses and the area under the curve (AUC) were used to estimate the predictive ability (mortality) of the scoring systems on admission and the maximum value. Results. Mortality among the 41 patients included in this study was 44%. On admission, the mean APACHE II (p=0.035), APACHE III (p=0.003), SAPS II (p=0.001), and SOFA (p=0.042) scores were significantly higher in nonsurvivors than in survivors. At maximum score, APACHE II (p=0.009), APACHE III (p<0.001), and SAPS II (p<0.001) appeared to have higher significance. On admission, the discrimination for APACHE III was 0.786, for SAPS II 0.790, and for APACHE II 0.691. The maximum-score AUC for APACHE II was 0.726, for APACHE III 0.827, and for SAPS II 0.832. Elebute-Stoner and SOFA did not yield valuable results at maximum score or, in the case of Elebute-Stoner, on admission. Conclusion. These results suggest that at the time of diagnosis and at maximum value, the SAPS II, APACHE III, and APACHE II scores may be useful in predicting a high probability of survival of patients with CS complicating AMI. The maximum value of the APACHE II score was also significantly higher (p=0.009) for nonsurvivors (36.0±7.3) than for survivors (29.1±8.4; . Tab. 4).
Keywords
APACHE III score
Among the survivors, the initial APACHE III score was 96.4±34.0. The APACHE III score on admission was significantly higher in nonsurvivors (127.9±26.8, p=0.003; . Tab. 3).
The maximum APACHE III scores of survivors (104.4±29.9) and nonsurvivors (139.2±23.0) also differed significantly (p<0.001; . Tab. 4).
Elebute-Stoner score
The mean Elebute-Stoner scores were 11.1±4.1 for nonsurvivors and 10.7±4.1 for survivors, determined at the time of CS diagnosis (p=NS; . Tab. 3).
The maximum value of the ElebuteStoner score showed similar results: The Elebute-Stoner score in survivors was 13.0±3.8 and in nonsurvivors it was 14.1±4.5 (p=NS; . Tab. 4). 
SOFA score
The SOFA score was 9.8±3.2 in survivors at admission and 11.8±2.8 in nonsurvi vors (p=0.042). There was no significant difference in the maximum SOFA scores (. Tab. 3, 4).
SAPS II score
The SAPS II score was 57.0±16. 
Maximum value and survival
No correlation between maximum value and death was determined for the mean ingful scores of APACHE II, APACHE III, and SAPS II. However, most survivors had their maximum score on admission (. Fig. 2 ).
ROC and discrimination
ROC curves were calculated for the initial scores demonstrating a relative accuracy of the variables in predicting survival and are depicted in . Fig. 3 . ROC curves for maximum score values were illustrated in . At the time of CS diagnosis, the cut off value for APACHE III was >122.5, for SAPS II >66, and for APACHE II >31.5. The sensitivity and specificity of the SOFA and Elebute-Stoner scores were not com parable with the general scoring systems.
At the maximum values, the cutoff point for APACHE III was >122.5, for APACHE II >32.5, and for SAPS II >74, which demonstrates more valid results than the SOFA and Elebute-Stoner sys tems. The cutoff points at admission and maximum value are almost the same for the APACHE II, APACHE III, and SOFA systems, with a higher sensitivity and specificity at the maximum score (. Tab. 5).
Discussion
Urgent reperfusion of the infarctrelated artery (IRA) is essential in the manage ment of patients with AMI and CS [16, 20] . Despite reperfusion, mortality remains at almost 50% [2] due to low cardiac output, poor coronary perfusion, and worsening cardiac contractility, even though inotro pic and vasopressor support is given [17] . Recently, it has been shown that this ini tiates a systemic inflammatory process characterized by SIRS and subsequent ly MODS or sepsis, leading to decreased myocardial contractility [21] . The inflam matory stimulation on the endothelium of the blood vessels generates inducible ni tric oxide synthase and hence nitric oxide [15] , which also depresses cardiac func tion [3] . We believe mortality from AMI related CS results from a progression from initial hemodynamic instability followed by SIRS, sepsis, MODS, and finally death due to multiple organ failure. For this rea son, we also decided to include the Ele bute-Stoner and SOFA scores, besides APACHE II, APACHE III, and SAPS II.
The majority of scoring systems focus on mortality as the main outcome in a homogeneous population-not for an individual patient. Several authors have addressed the performance of mortali ty prediction models in subgroups of pa tients, defined by the same underlying dis ease or the same cause for intensive care admission [7, 11] . The aim of this study was to assess whether the APACHE II/III, Elebute-Stoner, SOFA, or SAPS II scores, determined on the day of diagnosis and at their maximum value, can predict mortal ity in patients with infarctionrelated CS.
Scoring in cardiogenic shock
We found that survivors of AMIrelated CS had significantly lower initial APACHE II/III, SAPS II, and SOFA scores. In con trast, nonsurvivors had significantly high er initial scores. When examining the maximum value, only the APACHE II/ III and SAPS II scores showed significant differences in survivors and nonsurvivors. With regard to risk stratification, the ini tial scores reflect the possibility of death after admission to hospital. By contrast, the maximum score value indicates the worst point, which could be the angular point of disease or the last scoring value before death, and is influenced by therapy. As demonstrated, there was no significant coherence between the maximum value and death. Within the group of survivors, the maximum value was found on admis sion, which could be interpreted to be the result of the effectiveness of therapies. The AMI with CS population appears to be more heterogeneous and shows a great spectrum of morbidity at presenta tion (and hence in initial and maximum scores). This spectrum can be used to pre dict mortality even at the time of admis sion to hospital. In simple terms, our da ta suggest that patients who have an ini tial APACHE III score threshold of 122.5 (SAPS II score >66 and APACHE II score >31.5) are at a substantially higher risk of death. This is also true for the analysis of the maximum values of APACHE III, SAPS II, and APACHE II. This heteroge neity of organ dysfunction in patients with CS is also reflected in the various sub groups identified in the SHOCK trial reg istry [27, 28] . Our study showed promis ing results for the SAPS II > APACHE III > APACHE II scores, with an excellent discrimination power. The discrimina tion between survivors and nonsurvivors appeared to be superior for the SAPS II and the APACHE III systems and accept able for the APACHE II system. The Ele bute-Stoner and SOFA scores were not able to determine the prognosis of CS pa tients since there was no significant differ ence between survivors and nonsurvivors. Some scores are accurate in assessing the risk of morbidity and mortality in shock patients, among which the APACHE III is the most accurate. How ever, it is more timeconsuming and expensive than the APACHE II [41] . Knaus et al. [23] studied 17,740 patients and showed an AUC of 0.90 on admission and an aver age admission score of 50 points for the APACHE III. In a study by Reina et al. [35] of 1,711 patients with AMI, the AUC was 0.84 with a sensitivity of 75.80 and a specificity of 75.90. In 2001, Markgraf and coworkers [26] showed an AUC of 0.846 for APACHE III in 1,772 interdiscipli nary ICU patients. In contrast to all oth er studies, we only included patients with CS, which could explain the slightly lower results.
The SAPS II score showed excellent results for both admission and maxi mum value, while cardiologic patients were excluded from the validation of this scoring system [24] . Schuster et al. [38] showed good results for these patients in 1997: In the subgroup of patients with AMI, the inhospital mortality was 15.6%, AUC was 0.905, and the average score was 28.3. Our results demonstrate much higher values on admission, for maxi mum score, and also in mortality, prob ably because the patients were suffering from CS complicating AMI. Mentnitz and colleagues [29] demonstrated that the SAPS II score was of good assistance in mortality evaluation in cardiac patients.
An interesting evaluation of APACHE III and SAPS II in patients with AMI found results similar to ours. In contrast to our study, Reina et al. [35] showed much low er mean values on admission for SAPS II in survivors and nonsurvivors (33.3 and 49.2, respectively) . This demonstrates the difference between AMI and AMI leading to CS and also the high mortality of CS.
The APACHE II score is probably the most extensively used and recognized scoring system, which was primarily de signed to predict mortality of patients in ICUs. In the study of Goel et al. [12] , the APACHE II score was found to be use ful in predicting longterm mortality for COPD patients admitted outside the ICU. Riberio and Kowalsky found APACHE II useful in predicting perioperative com plications in patients with oropharyngeal cancer [8] . In the original paper of Knaus et al. [22] , the APACHE II showed a high er AUC at admission (0.86) in the sub group of patients with CS and a mortal ity of 33%. Reasons for these differences could be the small sample size of our study and that all the patients in our investiga tion only developed CS after AMI.
The SOFA and Elebute-Stoner scores were designed for detecting and scoring inflammation, SIRS, sepsis, and MODS [9, 40] , also an important factor of mor tality in CS [15, 21] . Several studies have shown that there are significant differenc es in the value of the SOFA and ElebuteStoner score for differentiation of mor tality or MODS. Oda et al. [31] had sim ilar cutoff values at admission with ours, with a higher sensitivity and specificity (71.3 and 76.9%, respectively); however, they focused on MODS. Another study by Moreno et al. [30] that included 1,449 interdisciplinary ICU patients, found an AUC of 0.847 and 0.772 for the for the maximum SOFA score on admission. In comparison to our study, a trial by Jans sens et al. [19] showed that the AUC of 303 cardiac and pneumology patients was 0.86 for the maximum SOFA score.
The Elebute-Stoner score was not able to display differences in the admis sion and maximum values of CS patients. In contrast to our results, the original pa per of Elebute and Stoner showed a sig nificant distinction between survivors and nonsurvivors at a cutoff of 20 points for [33] . The APACHE II/III or SAPS II scores were recorded on the day of CS diagnosis and at their maximum value; it is, however, possible that some of the nonsurvivors developed sepsis and MODS after diagnosis and therefore led to increased scores in the course of the ill ness. The role of inflammation in CS is be coming more known, but it seems that the influence of the inflammatory reaction on these scoring systems is not high enough. Although the SOFA score was higher in nonsurvivors than in survivors at the time of CS diagnosis, at its maximum val ue it was not an independent predictor of mortality. While the Elebute-Stoner and SOFA scores were slightly higher in non survivors, the calibration sensitivity and specificity of these scores were poor. The characteristics of patients treated in differ ent ICUs are not the same. Different pa tient groups may develop different pat terns of organ dysfunction and scores dur ing CS. Little is known about the distribu tion and time course of organ failure in CS patients. With this study, we were able to show the effectiveness of the APACHE II/ III and SAPS II scores in CS patients.
It is also important to consider serial scoring, which looks at the effectiveness of therapies and the trend during hospitali zation [42, 43] . This aspect and the ana lysis of scorespecific subscores, especially the question on the role of inflammation and organ dysfunction, are very interest ing, and we are currently analyzing these data to publish them soon.
Limitations
There are several limitations in our study. The small sample size is the most impor tant limitation, since it may influence the evaluation of the calibration and discrim ination of the scores. Further, this study was performed within a single ICU. Since the severity of underlying disease, the age of the patients, and therapy protocols are different among ICUs, each ICU needs to determine its own cutoff points for each score even for different patient groups. Moreover, a higher lead time bias between the onset of illness or the most severe peri od of disease and the calculation of scores may also contribute to the performance of the scoring systems.
Conclusion
The present study suggests scoring systems can play a role in the prognosis assessment of patients with AMI complicated by CS. In this single-center registry, we were able to demonstrate the reliable discrimination of the APACHE III, SAPS II, and APACHE II scoring systems. In order to better evaluate these scoring systems in patients with CS, large-scale multicenter clinical studies should follow.
